Entrada Therapeutics Inc. (TRDA)

NASDAQ: TRDA · Real-Time Price · USD

9.09

-0.04 (-0.44%)

At close: May 01, 2025, 3:59 PM

9.05

-0.39%

After-hours: May 01, 2025, 04:57 PM EDT

-0.44% (1D)

Bid	8.45
Market Cap	341.55M
Revenue (ttm)	210.78M
Net Income (ttm)	65.63M
EPS (ttm)	1.68
PE Ratio (ttm)	5.41
Forward PE	-2.79
Analyst	Buy

Ask	9.5
Volume	83,822
Avg. Volume (20D)	135,257
Open	9.22
Previous Close	9.13
Day's Range	8.85 - 9.22
52-Week Range	7.10 - 21.79
Beta	0.03

About TRDA

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also eng...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 29, 2021

Employees 183

Stock Exchange NASDAQ

Ticker Symbol TRDA

Website https://www.entradatx.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for TRDA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 208.20% from the latest price.

Stock Forecasts

Next Earnings Release

Entrada Therapeutics Inc. is scheduled to release its earnings on May 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

8 months ago

+11.26%

Entrada Therapeutics shares are trading higher. Th... Unlock content with Pro Subscription

News

3 days ago · zacks.com

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.29 per share a yea...

2 months ago · seekingalpha.com

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 milli...